A 2-arm, Prospective, Randomized, Controlled, Open-label, 12 Month Phase III Trial to Evaluate the Efficacy of Everolimus in Combination With a Centre Specific Standard Immunosuppressive Regimen Consisting of CNI, MPA and Steroids Versus a Standard Triple Immunosuppressive Regimen in Lung Transplant Recipients.

Trial Profile

A 2-arm, Prospective, Randomized, Controlled, Open-label, 12 Month Phase III Trial to Evaluate the Efficacy of Everolimus in Combination With a Centre Specific Standard Immunosuppressive Regimen Consisting of CNI, MPA and Steroids Versus a Standard Triple Immunosuppressive Regimen in Lung Transplant Recipients.

Completed
Phase of Trial: Phase III

Latest Information Update: 06 Jun 2018

At a glance

  • Drugs Everolimus (Primary) ; Ciclosporin; Corticosteroids; Mycophenolic acid; Tacrolimus
  • Indications Lung transplant rejection
  • Focus Pharmacodynamics
  • Acronyms 4EVERLUNG
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 06 Jun 2018 Primary endpoint has been met. (Renal function measured by calculated Glomerular Filtration Rate (cGFR) Using Modification of Diet in Renal Disease (MDRD) Formula at 12 months) as per results presented at the 2018 American Transplant Congress
    • 06 Jun 2018 Results presented at the 2018 American Transplant Congress
    • 05 Apr 2017 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top